Verastem To Present Scientific Data Supporting FAK Inhibition In Combination With Immune Checkpoint Inhibitors At Immunotherapy World 2016
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at Immunotherapy World 2016 being held January 25-27, 2016 in Washington, DC.
“Over the past couple of years, exciting data have emerged from several research groups demonstrating the importance of FAK inhibition in the immuno-oncology arsenal,” said Dr. Jonathan Pachter, Verastem Head of Research.
“Over the past couple of years, exciting data have emerged from several research groups demonstrating the importance of FAK inhibition in the immuno-oncology arsenal,” said Dr. Jonathan Pachter, Verastem Head of Research.